|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2006-8-22
|
|
pubmed:abstractText |
The aims of this study were to evaluate the impact of the CYP2D6 polymorphism on both the steady-state plasma concentrations (Cp) and the clinical outcome of donepezil, a selective acetylcholinesterase inhibitor used in the treatment of Alzheimer's disease (AD).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0031-6970
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
62
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
721-6
|
|
pubmed:meshHeading |
pubmed-meshheading:16845507-Aged,
pubmed-meshheading:16845507-Aged, 80 and over,
pubmed-meshheading:16845507-Alzheimer Disease,
pubmed-meshheading:16845507-Cholinesterase Inhibitors,
pubmed-meshheading:16845507-Cytochrome P-450 CYP2D6,
pubmed-meshheading:16845507-Female,
pubmed-meshheading:16845507-Genotype,
pubmed-meshheading:16845507-Humans,
pubmed-meshheading:16845507-Indans,
pubmed-meshheading:16845507-Male,
pubmed-meshheading:16845507-Middle Aged,
pubmed-meshheading:16845507-Piperidines,
pubmed-meshheading:16845507-Polymorphism, Genetic
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients.
|
|
pubmed:affiliation |
DISCAFF Department, Amedeo Avogadro University of Eastern Piedmont, Via Bovio, 6, 28100 Novara, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
